The stresses and sleep disturbances of shift work can lead to major mental health issues, as well as workplace challenges, including safety concerns and poor on-the-job performance.
Women with insomnia were more likely to report prior or current depression than women without insomnia in the study.
The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.
Individuals most at risk for neurobehavioral performance impairment during sleep deprivation can be accurately identified by a visual psychomotor vigilance task.
Approximately 20% of women experienced an increase in sleep issues during the presurgery period, although for the majority of women sleep trajectories were generally stable pre- and postsurgery.
Researchers explored habitual sleep, social jetlag, and day-to-day variations in sleep among youth with DSWPD compared with healthy controls.
In children with fragile X syndrome (FXS), Down syndrome (DS), and Williams syndrome (WS), disrupted sleep may adversely affect language development.
Suvorexant improves total sleep time (TST) in patients with probable Alzheimer disease (AD) dementia and insomnia.
Previous studies have shown that sleep efficiency decreases with age, but additional factors may have an important role.
For persons with a previous diagnosis of generalized anxiety disorder (GAD), factors associated with being in complete mental health (CMH) include female gender, older age, being married, and reporting good to excellent physical health.